Breaking News Instant updates and real-time market news.

ELNK

EarthLink

$5.41

-0.11 (-1.99%)

, CVGI

Commercial Vehicle Group

$5.05

-0.2 (-3.81%)

04:55
11/30/16
11/30
04:55
11/30/16
04:55

Bofa/Merrill to hold a conference

2016 Leveraged Finance Conference is being held in Boca Raton, FL on November 29-30.

ELNK

EarthLink

$5.41

-0.11 (-1.99%)

CVGI

Commercial Vehicle Group

$5.05

-0.2 (-3.81%)

PERY

Perry Ellis

$26.14

0.51 (1.99%)

RDN

Radian Group

$14.65

0.11 (0.76%)

KAR

KAR Auction

$41.65

-0.05 (-0.12%)

SBRA

Sabra Health Care

$22.47

0.93 (4.32%)

HL

Hecla Mining

$6.24

0.08 (1.30%)

AMAG

AMAG Pharmaceuticals

$33.70

0.85 (2.59%)

DOOR

Masonite

$64.90

-0.65 (-0.99%)

CVA

Covanta

$14.55

-0.3 (-2.02%)

VSTO

Vista Outdoor

$40.24

-0.26 (-0.64%)

HUN

Huntsman

$19.05

0.43 (2.31%)

COMM

CommScope

$36.23

0.4 (1.12%)

LKSD

LSC Communications

$20.48

0.46 (2.30%)

AXL

American Axle

$15.37

-0.22 (-1.41%)

LKQ

LKQ Corp.

$33.01

-0.26 (-0.78%)

ABG

Asbury Automotive

$58.70

-0.3 (-0.51%)

MGI

MoneyGram

TROX

Tronox

$11.38

0.38 (3.45%)

  • 30

    Nov

  • 30

    Nov

  • 02

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Jan

  • 10

    Jan

ELNK EarthLink
$5.41

-0.11 (-1.99%)

11/08/16
DRXL
11/08/16
DOWNGRADE
DRXL
Hold
EarthLink downgraded to Hold from Buy at Drexel Hamilton
EarthLink (ELNK) is being acquired by Windstream (WIN) for .818 shares of Winstream stock, or approximately $5.96 per a share.
10/17/16
COWN
10/17/16
INITIATION
Target $8
COWN
Outperform
EarthLink initiated with an Outperform at Cowen
Cowen analyst Jonathan Charbonneau initiated EarthLink with an Outperform and an $8 price target saying he expect stronger revenue trends, stable margins, and another year of meaningful FCF generation in 2017, resulting in multiple expansion.
CVGI Commercial Vehicle Group
$5.05

-0.2 (-3.81%)

05/17/16
GHSC
05/17/16
UPGRADE
Target $5
GHSC
Buy
Commercial Vehicle Group upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Michael Shlisky upgraded Commercial Vehicle Group to Buy and raised its price target to $5 from $3 following recent management meetings. The new CEO seems confident that cost reductions can accelerate from here as footprint rationalizations ramp and standardization of processes are rolled out, the analyst wrote. Further, Shlisky said management noted breakeven has been significantly reduced to the point where the company can make money with revenues well below $150M per quarter.
10/20/16
10/20/16
NO CHANGE

September NA Class 8 truck data a negative, says Seaport Global
Seaport Global analyst Michael Shlisky said September North American truck data is a negative for the Class 8 sector. Class 8 sales declined 24% year-over-year, versus down 28% in Q3, while production declined 36%, down 35% in Q3, and orders declined 29%, versus down 40% in Q3. The analyst said PACCAR production was inline with his model for the quarter and continues to view the company as best positioned in the current environment.
07/06/16
GHSC
07/06/16
DOWNGRADE
GHSC
Neutral
Commercial Vehicle Group downgraded to Neutral from Buy at Seaport Global
Seaport Global analyst Michael Shlisky downgraded Commercial Vehicle Group to Neutral citing valuation and maintained its $5 price target on shares.
PERY Perry Ellis
$26.14

0.51 (1.99%)

06/21/16
BMUR
06/21/16
INITIATION
Target $26
BMUR
Buy
Perry Ellis assumed with a Buy at Brean Capital
Target $26.
06/21/16
BMUR
06/21/16
NO CHANGE
Target $26
BMUR
Buy
Perry Ellis coverage assumed with a Buy at Brean Capital
Brean Murray analyst Eric Tracy assume coverage on Perry Ellis with a Buy rating and $26 price target. The analyst expects accelerating revenue growth in 2H 2016 that should help offset continued pressure in the domestic wholesale channel and sees a decent margin expansion opportunity, supported by lower markdowns, and accretive mix shifts towards international.
06/21/16
06/21/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Perry Ellis (PERY) assumed with a Buy at Brean Capital. 2. Alcobra (ADHD) reinstated with a Buy at Roth Capital. 3. G-III Apparel (GIII) assumed with a Buy at Brean Capital. 4. US Foods (USFD) initiated with a Buy at Guggenheim. 5. PRA Health (PRAH) initiated with a Neutral at Credit Suisse and with an Equal-Weight at First Analysis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/16
BMUR
08/19/16
NO CHANGE
Target $25
BMUR
Buy
Perry Ellis sentiment largely washed out, says Brean Capital
Brean Capital analyst Eric Tracy noted Perry Ellis reported better than feared results. The analyst cited continued tight inventory management and disciplined expense control. The company lowered guidance on due to an uncertain macro environment but Tracy believes management is making the right decisions to reposition the brand. Tracy reiterated his Buy rating as investor sentiment appears to be washed out and he lowered his price target to $25 from $26 on Perry Ellis shares.
RDN Radian Group
$14.65

0.11 (0.76%)

10/17/16
BOFA
10/17/16
INITIATION
Target $18
BOFA
Buy
Radian Group initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Mihir Bhatia initiated Radian Group with a Buy and an $18 price target.
06/30/16
FBRC
06/30/16
UPGRADE
Target $14
FBRC
Outperform
Radian Group upgraded to Outperform from Market Perform at FBR Capital
FBR Capital analyst Patrick Kealey upgraded Radian Group to Outperform with a $14 price target saying current share levels offer an "excellent buying opportunity." The analyst believes Federal Housing Administration competitive pricing concerns are overdone.
10/28/16
COMP
10/28/16
DOWNGRADE
COMP
Neutral
Radian Group downgraded to Neutral from Buy at Compass Point
Compass Point downgraded Radian Group to Neutral and maintained its $16.50 price target citing fair valuation and the potential for an FHA MIP reduction.
04/04/16
DBAB
04/04/16
INITIATION
Target $16
DBAB
Buy
Radian Group initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Phil Stefano initiated Radian Group with a Buy and $16 price target.
KAR KAR Auction
$41.65

-0.05 (-0.12%)

08/26/16
SUSQ
08/26/16
INITIATION
Target $50
SUSQ
Positive
KAR Auction initiated with a Positive at Susquehanna
Susquehanna analyst Ali Faghri initiated KAR Auction with a Positive and $50 price target.
08/04/16
BARD
08/04/16
NO CHANGE
Target $46
BARD
Outperform
KAR Auction weakness a buying opportunity, says Baird
Baird said a pullback in KAR Auction would be a good buying opportunity. The firm likes the stock for defensive-minded investors looking for high-quality businesses with visibility into future revenue streams. Baird reiterated its Outperform rating and $46 price target on KAR Auction shares.
07/14/16
NRCS
07/14/16
DOWNGRADE
NRCS
Neutral
KAR Auction downgraded to Neutral from Buy at Northcoast
05/05/16
BARD
05/05/16
NO CHANGE
Target $44
BARD
Outperform
KAR Auction price target raised to $44 from $40 at Baird
Baird raised its price target on KAR Auction to $44 from $40 following Q1 results the firm called impressive, citing the company's raised core guidance and solid execution. Baird said it would be more aggressive on pullbacks and reiterated its Outperform rating on KAR Auction shares.
SBRA Sabra Health Care
$22.47

0.93 (4.32%)

07/25/16
07/25/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Deere (DE) downgraded to Underweight from Neutral at Piper Jaffray with analyst Brett Wong citing expectations that the current agriculture downturn is going to persist in 2017 for a fourth consecutive year. 2. Whirlpool (WHR) downgraded to Market Perform from Strong Buy at Raymond James with analyst Sam Darkatsh saying risk/reward is no longer skewed positively given increasingly more difficult comps, a seasonally heavier promotional environment, and higher cost inflation for 2017. 3. SunTrust (STI) downgraded to Buy from Conviction Buy at Goldman with analyst Ryan Nash citing headwinds from net margin pressure and potential elevated expenses in the second half of 2016. 4. Tableau (DATA) downgraded to Hold from Buy at Deutsche Bank analyst Karl Keirstead saying he's incrementally concerned about price discounting and competition after speaking to the company's partners and customers. 5. Sabra Health Care (SBRA) downgraded to Underperform from Neutral at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/25/16
BOFA
07/25/16
DOWNGRADE
BOFA
Underperform
Sabra Health Care downgraded to Underperform from Neutral at BofA/Merrill
08/25/16
BTIG
08/25/16
INITIATION
BTIG
Neutral
Sabra Health Care initiated with a Neutral at BTIG
06/23/16
CANT
06/23/16
INITIATION
Target $28
CANT
Buy
Sabra Health Care initiated with a Buy at Cantor
Cantor analyst Joe France initiated Sabra Health Care with a Buy and $28 price target.
HL Hecla Mining
$6.24

0.08 (1.30%)

11/10/16
BMOC
11/10/16
DOWNGRADE
BMOC
Underperform
Hecla Mining downgradedat BMO Capital
As noted earlier, BMO Capital downgraded Hecla to Underperform from Market Perform. Analyst Jessica Fung downgraded the stock based on valuation. Target $6.50.
09/06/16
RODM
09/06/16
INITIATION
Target $9
RODM
Buy
Hecla Mining initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Heiko Ihle started Hecla Mining with a Buy rating and $9 price target.
10/25/16
ADAM
10/25/16
INITIATION
Target $6
ADAM
Hold
Hecla Mining initiated with a Hold at Canaccord
Canaccord analyst Peter Bure initiated Hecla Mining with a Hold rating and $6 price target as he believes silver prices will continue to appreciate over the next 12-18 months as zinc and lead mine closures impact supply.
11/10/16
BMOC
11/10/16
DOWNGRADE
BMOC
Underperform
Hecla Mining downgraded to Underperform from Market Perform at BMO Capital
AMAG AMAG Pharmaceuticals
$33.70

0.85 (2.59%)

09/01/16
LEER
09/01/16
NO CHANGE
Target $36
LEER
Outperform
AMAG Pharmaceuticals price target lowered to $36 from $40 at Leerink
Leerink analyst Joseph Schwartz lowered his price target for AMAG Pharmaceuticals (AMAG) to $36 from $40, saying he is wary that its Makena auto-injector will garner increased attention in 2018, similar to Mylan's (MYL) EpiPen. The analyst believes AMAG Pharmaceuticals' auto-injector will receive FDA approval but it remains to be seen whether approval timing and future potential achieve the company's expectations. He reiterates an Outperform rating on the AMAG Pharmaceuticals' shares.
05/17/16
LEER
05/17/16
NO CHANGE
Target $40
LEER
Outperform
ANI, Aspen deal only incremental negative for AMAG Pharma Makena, says Leerink
Leerink analyst Joseph Schwartz says ANI Pharmaceuticals (ANIP) announced an agreement with Aspen Global for Hydroxyprogesterone Caproate Injection, with Aspen responsible for supplying the finished goods and ANIP responsible for U.S. distribution. The analyst sees this deal as only an "incremental negative" for AMAG Pharmaceuticals' (AMAG) Makena sales in the second half of 2016. While Schwartz notes that the magnitude of this threat is still "poorly defined," he believes it will be less negative than if U.S. commercial rights had been out licensed to a major generic manufacturer with an existing commercial infrastructure in maternal health. Schwartz reiterates an Outperform rating and $40 price target on AMAG's shares.
10/27/16
10/27/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Fossil (FOSL) initiated with an Underperform at Buckingham. 2. AMAG Pharmaceuticals (AMAG) initiated with a Buy at Needham. 3. Ohr Pharmaceutical (OHRP) initiated with a Buy at H.C. Wainwright. 4. Sarepta (SRPT) initiated with an Equal Weight at Morgan Stanley. 5. CrossAmerica (CAPL) initiated with a Sector Perform at RBC Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/26/16
NEED
10/26/16
INITIATION
Target $40
NEED
Buy
AMAG Pharmaceuticals initiated with a Buy at Needham
Needham analyst Serge Belanger initiated AMAG Pharmaceuticals with a Buy and a $40 price target.
DOOR Masonite
$64.90

-0.65 (-0.99%)

11/10/16
STFL
11/10/16
UPGRADE
Target $72
STFL
Buy
Masonite upgraded to Buy from Hold at Stifel
Stifel analyst John Baugh upgraded Masonite to Buy and raised its price target to $72 from $62 following the strong Q3 report combined with attractive valuation.
08/12/16
BARD
08/12/16
NO CHANGE
Target $75
BARD
Outperform
Masonite weakness a buying opportunity, says Baird
Baird said the long-term story for Masonite remains intact and they would use the weakness in the shares as a buying opportunity. The firm believes the company's bumpy Q2 results were due to one-time events. Baird reiterated its Outperform rating on Masonite shares, as they see considerable earnings power, structural industry change, and solid free cash flow.
08/15/16
RBCM
08/15/16
NO CHANGE
RBCM
Masonite weakness creates buying opportunity, says RBC Capital
RBC Capital analyst Robert Wetenhall says that the 7.9% decline in Masonite's stock following its Q2 results was due to concerns about the company's pricing and profitability that "appear to be largely unwarranted." The analyst says that the company's pricing was "favorable," but "was obfuscated by an unfavorable mix due to increased sales of less expensive interior doors." He thinks that the company's pricing trends will continue to be positive, and notes that a one-time $10M investment by the company also lowered its profits.
07/05/16
RBCM
07/05/16
NO CHANGE
RBCM
Whirlpool, Masonite look oversold on Brexit fears, says RBC Capital
RBC Capital says that Whirlpool (WHR) has dropped 6.8% since the Brext vote, while Masonite (DOOR) has retreated 4.7%. The firm estimates that, in a worst-case scenario, Whirlpool's 2H16 EBITDA would come in 3.6% lower than the firm's current estimate as a result of Brexit, while Masonite's 2H16 EBITDA would be 2.8% below the firm's current outlook.
CVA Covanta
$14.55

-0.3 (-2.02%)

11/07/16
LEHM
11/07/16
UPGRADE
Target $16
LEHM
Overweight
Covanta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Jon Windham upgraded Covanta to Overweight saying the 8% pullback in shares since the Q3 results provides a buying opportunity. The analyst views Covanta's fundamentals as unchanged and he keeps a $16 price target for the shares.
11/07/16
LEHM
11/07/16
UPGRADE
Target $70
LEHM
Overweight
Waste Management upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Jon Windham upgraded Waste Management (WM) to Overweight saying the recent pullback in shares provides a buying opportunity given the company's "strong" underlying fundamentals. The analyst keeps a $70 price target for the shares. Windham this morning also upgraded Covanta (CVA) to Overweight and downgraded Clean Harbors (CLH) to Equal Weight.
08/25/16
MACQ
08/25/16
INITIATION
Target $18
MACQ
Neutral
Covanta initiated with a Neutral at Macquarie
Macquarie analyst Hamzah Mazari initiated Covanta with a Neutral and $18 price target.
09/22/16
OPCO
09/22/16
NO CHANGE
Target $20
OPCO
Outperform
Oppenheimer sees Covanta as attractive yield play on recent pullback
Oppenheimer analyst Noah Kaye notes Covanta's shares are off 10% quarter to date despite the company reaffirming 2016 guidance in August and a largely unchanged commodity outlook. While the analyst believes Covanta's management and board will likely decide to keep the dividend at current levels in 2017, he expects EBITDA and cash generation from the Dublin project, Manhattan MTS and other initiatives to decrease leverage and provide cushion for a 2018 dividend increase. Kaye sees the shares as an attractive yield play on the recent pullback, and reiterates an Outperform rating and $20 price target on the stock.
VSTO Vista Outdoor
$40.24

-0.26 (-0.64%)

08/30/16
KEYB
08/30/16
UPGRADE
Target $48
KEYB
Overweight
Vista Outdoor upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Scott Hamann upgraded Vista Outdoor to Overweight saying the recent pullback in the shares has brought an attractive entry point. The current valuation largely prices in a potential guidance cut while the ammo channel is seeing continued momentum, Hamann tells investors in a research note. He has a $48 price target for the shares.
09/19/16
KING
09/19/16
INITIATION
Target $45
KING
Buy
Vista Outdoor initiated with a Buy at CL King
CL King analyst Scott Stember initiated Vista Outdoor with a Buy and a $45 price target.
10/17/16
JEFF
10/17/16
NO CHANGE
Target $54
JEFF
Buy
Vista Outdoor shares oversold after pullback, says Jefferies
Jefferies analyst Greg Konrad views Vista Outdoor as oversold with the stock down 26% since the company reported Q1 results. The share price is now "disconnected from the financial prospects of the business," Konrad tells investors in a research note. He expects the Q2 results to show a "modest" improvement with a more "pronounced recovery" in the second half of FY17. Konrad keeps a Buy rating on Vista with a $54 price target.
08/12/16
ROTH
08/12/16
NO CHANGE
Target $51
ROTH
Buy
Vista Outdoor price target lowered to $51 from $57 at Roth Capital
Roth Capital analyst Dave King lowered his price target for Vista Outdoor to $51 from $57 after the company's quarterly results "surprisingly" fell short of estimates amid a shift in consumer spending, capacity constraints for certain centerfire ammunition, the timing of international orders, and the challenging retail environment. Nonetheless, the analyst reiterates a Buy rating on the shares to reflect Vista Outdoor's leading market share and "strong" management team.
HUN Huntsman
$19.05

0.43 (2.31%)

02/11/16
KEYB
02/11/16
DOWNGRADE
KEYB
Sector Weight
Huntsman downgraded to Sector Weight from Overweight at KeyBanc
03/07/16
UBSW
03/07/16
NO CHANGE
Target $14
UBSW
Buy
Huntsman shares offer compelling opportunity, says UBS
UBS said Huntsman shares offer a compelling opportunity, citing the earnings potential of its cyclical businesses and its review of alternatives for its TiO2 division. UBS reiterated its Buy rating and $14 price target on Huntsman shares.
07/11/16
NOMU
07/11/16
NO CHANGE
NOMU
Buy
Olin and Huntsman remain Top Picks for 2H 2016 at Nomura
Nomura analyst Aleksey Yefremov said Olin (OLN) and Huntsman (HUN) remain Top Picks heading into 2H 2016. The analyst sees stronger evidence of recovery in chlor-alkali and TiO2, combined with above-average FCF yields for both Buy rated names.
COMM CommScope
$36.23

0.4 (1.12%)

07/12/16
LBOW
07/12/16
NO CHANGE
LBOW
CommScope seeing lower revenue from AT&T, says Longbow
Longbow says that AT&T's (T) spending on CommScope's (COMM) solutions unexpectedly slowed in late Q2 and into Q3. The firm says its source estimates that AT&T's spending has dropped by three percentage points. As a result, Longbow estimates that Commscope's North American 2016 revenue is now flat to up low single digits versus its previous outlook of up low single digits. However, the firm keeps a Buy rating on the shares. It adds that Crown Castle (CCI), American Tower (AMT), SBA Communications (SBAC), and Ericsson (ERIC) have a negative read through from the news.
07/29/16
DBAB
07/29/16
NO CHANGE
Target $35
DBAB
Buy
CommScope selloff a buying opportunity, says Deutsche Bank
Deutsche Bank analyst Vijay Bhagavath recommends using the post-earnings pullback in shares of CommScope as a buying opportunity. The company reported "solid" Q2 results and its valuation story remains intact, Bhagavath tells investors in a post-earnings research note. He lowered his price target for the shares to $35 from $36 and keeps a Buy rating on the name.
09/20/16
MSCO
09/20/16
INITIATION
Target $35
MSCO
Equal Weight
CommScope initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Meta Marshall initiated CommScope with an Equal Weight and a a$35 price target.
10/24/16
JPMS
10/24/16
NO CHANGE
JPMS
CommScope may be negatively impacted by T-Mobile capex cut, says JPMorgan
JPMorgan analyst Rod Hall said the implied cut in T-Mobile's (TMUS) capex deterioration may negatively impact wireless vendors such as CommScope (COMM).
LKSD LSC Communications
$20.48

0.46 (2.30%)

AXL American Axle
$15.37

-0.22 (-1.41%)

11/09/16
11/09/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. JPMorgan (JPM) downgraded to Neutral from Outperform at Baird with analyst David George noting the stock's outperformance and the higher re-rating of its valuation multiple. 2. GoPro (GPRO) downgraded to Neutral from Outperform at Wedbush, to Market Perform from Outperform at Raymond James, and to Sell from Neutral at Dougherty. 3. Universal Health (UHS) downgraded to Neutral from Buy at BofA/Merrill, to Neutral from Buy at Mizuho, and to Market Perform from Outperform at Avondale. 4. Globus Medical (GMED) downgraded to Market Perform from Outperform at JMP Securities, to Perform from Outperform at Oppenheimer, and to Market Perform from Outperform at William Blair. 5. Delphi (DLPH) and Magna (MGA) were downgraded to Underperform from Buy at BofA/Merrill while the firm downgraded Lear (LEA), American Axle (AXL), Adient (ADNT), and BorgWarner (BWA) to Underperform from Neutral. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/15/16
KEYB
11/15/16
DOWNGRADE
KEYB
Sector Weight
American Axle downgraded to Sector Weight from Overweight at KeyBanc
11/10/16
FBRC
11/10/16
DOWNGRADE
Target $12
FBRC
Underperform
American Axle downgraded to Underperform from Market Perform at FBR Capital
FBR Capital analyst Christopher Van Horn downgraded American Axle to Underperform citing the peaking of annual car sales and uncertainty on the auto suppliers following the Donald Trump victory. The analyst lowered his price target for the shares to $12 from $16.
11/16/16
KEYB
11/16/16
DOWNGRADE
KEYB
Sector Weight
American Axle downgraded on acquisition, headwinds at KeyBanc
As noted earlier, KeyBanc downgraded American Axle (AXL) to Sector Weight from Overweight. Analyst Brett Hoselton says that the company's acquisition of Metaldyne (MPG) does not appear to have accomplished its goals of diversifying its geographic focus and its customer base. Additionally, the analyst expects the company to be hurt by slowing light vehicle production growth in North America and its loss of 25% of the GM (GM) replacement business.
LKQ LKQ Corp.
$33.01

-0.26 (-0.78%)

11/29/16
STFL
11/29/16
INITIATION
STFL
Buy
LKQ Corp. coverage resumed with a Buy at Stifel
Target $37.
10/05/16
SUSQ
10/05/16
NO CHANGE
Target $42
SUSQ
Positive
LKQ Corp. weakness a buying opportunity, says Susquehanna
Susquehanna analyst Ali Faghri said investors should use any weakness in LKQ Corp. as a buying opportunity ahead of improving fundamentals in coming years. The stock remains one of Faghri's favorite ideas as strong margin gains should limit any impact from an increase in salvage frequency. The shares remain undervalued on improving North American fundamentals, expansion opportunity in Europe, and moderating headwinds from foreign exchange. Faghri reiterated his Buy rating and $42 price target on LKQ shares.
04/29/16
WLSD
04/29/16
UPGRADE
WLSD
Buy
LKQ Corp. upgraded to Buy from Gradually Accumulate at Wellington Shields
08/25/16
SUSQ
08/25/16
INITIATION
Target $42
SUSQ
Positive
LKQ Corp. initiated with a Positive at Susquehanna
Susquehanna analyst Ali Faghri initiated LKQ Corp with a Positive and $42 price target.
ABG Asbury Automotive
$58.70

-0.3 (-0.51%)

11/16/16
KEYB
11/16/16
DOWNGRADE
KEYB
Sector Weight
Asbury Automotive downgraded to Sector Weight from Overweight at KeyBanc
09/13/16
WOLF
09/13/16
INITIATION
WOLF
Peer Perform
Asbury Automotive initiated with a Peer Perform at Wolfe Research (pre-open)
Pre-open, Wolfe Research Asbury Automotive with a Peer Perform given a negative macro backdrop and high leverage. The firm remains negative on the sector peak demand, a high level of subprime and lax credit standards in auto lending.
11/16/16
KEYB
11/16/16
DOWNGRADE
KEYB
Sector Weight
Asbury Automotive downgraded on sedan headwinds at KeyBanc
As noted earlier, KeyBanc downgraded Asbury Automotive to Sector Weight from Overweight. Analyst Brett Hoselton expects the company to be hurt by the declining market share of small to mid-size sedans. He believes that competition among OEMs in this group have increased, and he expects Asbury's profits to be pressured as a result of this trend. .
04/11/16
JEFF
04/11/16
INITIATION
Target $60
JEFF
Hold
Asbury Automotive initiated with a Hold at Jefferies
Jefferies analyst Bret Jordan started Asbury Automotive Group with a Hold rating and $60 price target.
MGI MoneyGram

02/12/16
FLTL
02/12/16
UPGRADE
FLTL
Strong Buy
MoneyGram upgraded to Strong Buy from Buy at Feltl
Feltl upgraded MoneyGram to Strong Buy citing solid Q4 results and guidance saying valuation is attractive. The firm maintained its $9 price target on MoneyGram shares.
02/22/16
NORL
02/22/16
INITIATION
NORL
Market Perform
MoneyGram initiated with a Market Perform at Northland
11/21/16
FLTL
11/21/16
DOWNGRADE
FLTL
Buy
MoneyGram downgraded to Buy from Strong Buy at Feltl
07/12/16
JPMS
07/12/16
DOWNGRADE
Target $8
JPMS
Neutral
MoneyGram downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Tien-tsin Huang downgraded MoneyGram (MGI) to Neutral saying "mixed news flow" could keep the stock range-bound for the foreseeable future. The analyst keeps an $8 price target for the shares. Huang this morning also upgraded FleetCor to Overweight from Neutral.
TROX Tronox
$11.38

0.38 (3.45%)

04/06/16
04/06/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Hibbett Sports (HIBB) downgraded to Underperform at BofA/Merrill citing the impact of the rapid growth of competitor and vendor owned e-commerce in its core small niche markets. BofA said Hibbett plans to build an e-commerce platform which is expected to launch in FQ4 2018, but it will likely negatively impact EBIT margins and earnings growth. 2. Tronox (TROX) downgraded to Sell at UBS by analyst John Roberts, who expects earnings for TiO2 producers to remain challenged in 2016. 3. EOG Resources (EOG) downgraded to Hold at Stifel based on "heightened oil price risk" amid what it sees as "mixed signals from OPEC ministers, ramping volumes from Iran, and potential backlash from Saudi Arabia." 4. Domtar (UFS) downgraded to Underperform from Neutral at BofA/Merrill. 5. Jernigan Capital (JCAP) downgraded to Sell from Hold at Wunderlich. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/06/16
UBSW
04/06/16
DOWNGRADE
Target $2.75
UBSW
Sell
Tronox downgraded to Sell from Neutral at UBS
UBS analyst John Roberts downgraded Tronox to Sell citing the stock's 75% rally over the past two months. The analyst expects earnings for TiO2 producers to remain challenged in 2016. He keeps a $2.75 price target for Tronox shares.

TODAY'S FREE FLY STORIES

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ABBV

AbbVie

$59.43

0.27 (0.46%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

18:29
12/04/16
12/04
18:29
12/04/16
18:29
Hot Stocks
AbbVie reports five-year IMBRUVICA data, updated RESONATE-2 data »

AbbVie (ABBV) announced…

ABBV

AbbVie

$59.43

0.27 (0.46%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

18:17
12/04/16
12/04
18:17
12/04/16
18:17
Hot Stocks
Celgene, Dana-Farber, U of Arkansas form Myeloma Genome Project »

Celgene, Dana-Farber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

ARQL

ArQule

$1.37

-0.01 (-0.72%)

18:12
12/04/16
12/04
18:12
12/04/16
18:12
Hot Stocks
ArQule reports data presentation on ARQ 092 in sickle cell disease »

ArQule announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$98.50

-0.44 (-0.44%)

, TWX

Time Warner

$93.80

-0.34 (-0.36%)

18:08
12/04/16
12/04
18:08
12/04/16
18:08
Hot Stocks
Box Office Battle: 'Moana,' 'Fantastic Beasts' win post-Thanksgiving weekend »

Disney's (DIS)…

DIS

Disney

$98.50

-0.44 (-0.44%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

VIA

Viacom

$40.35

-1 (-2.42%)

VIAB

Viacom

$36.52

-0.74 (-1.99%)

SNE

Sony

$28.06

-0.16 (-0.57%)

FOX

21st Century Fox

$27.37

-0.71 (-2.53%)

FOXA

21st Century Fox

$27.40

-0.8 (-2.84%)

LGF

Lionsgate

$22.72

0.02 (0.09%)

CMCSA

Comcast

$68.78

-1.08 (-1.55%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.